anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Airborne surface and underwater human pose recognition are crucial for various safety and surveillance applications, including the detection of individuals in distress or drowning situations. However, airborne optical cameras struggle to achieve simultaneous imaging of the surface and underwater because of limitations imposed by visible-light wavelengths. To address this problem, this study proposes the use of light detection and ranging (LiDAR) to simultaneously detect humans on the surface and underwater, whereby human poses are recognized using a neural network designed for irregular data. First, a temporal point-cloud dataset was constructed for surface and underwater human pose recognition to enhance the recognition of comparable movements. Subsequently, radius outlier removal (ROR) and statistical outlier removal (SOR) were employed to alleviate the impact of noise and outliers in the constructed dataset. Finally, different combinations of secondary sampling methods and sample sizes were tested to improve recognition accuracy using PointNet++. The experimental results show that the highest recognition accuracy reached 97.5012%, demonstrating the effectiveness of the proposed human pose detection and recognition method.
FIELD: medicine, cardiology, pharmacy. SUBSTANCE: invention relates to pharmaceutical preparations used in cardiovascular diseases. Invention relates to the development of pharmaceutical agent that comprises dipyridamole as an active component and special accessory components: microcrystalline cellulose, starch and/or modified starch and/or croscarmellose, lactose, stearic acid or its salts and aerosil taken in the corresponding ratio of components. Composition with the claimed ratio of components provides optimal physical-chemical and technological properties of medicinal form and high bioavailability of medicinal substance. EFFECT: valuable medicinal properties of agent. 6 cl, 1 ex
Provided is a weight management system using weight measurement and a competitive spirit. According to the weight management system using weight measurement and a competitive spirit of the present invention, a user can continuously check a weight change rate while measuring the weight, can visually check the same using a graph for a weight change for a specific period so as to have the pressure in accordance with an increase in the weight, and can take diet with some tension by accepting the necessity of a diet between users since the weight of the user and that of a competitor who has a body shape similar that of the user are compared. Also, the weight for each user is measured through a scale including a fingerprint recognizing device and a wireless communication module to indue an effective diet through a function of recommending a diet menu suitable for eating habits of the user and a diet exercise method suitable for a body shape of the user, and the body weight can be checked in real time in a user terminal owned by the user. In addition, a change in the weight for a predetermined period can be easily checked through a weight change rate and a graph by comparing the same with weight data measured in advance. Also, a desire for a diet is further motivated by inducing a competitive spirit between a plurality of users through comparison of features and the weight of a competitor who has a similar body shape with that of the user. Furthermore, a diet menu and a diet exercise method suitable for eating habits or a body shape of the user can be suggested.
Each probiotic capsule contains 180 mg of a standardized white to light beige fine powder consisting of freeze-dried cultures. Specifically, Bifidobacterium BB-12® and Lactobacillus rhamnosus LGG® (50%:50%). This product has a minimum potency of 6.5 billion (6.5E+9) CFU (ColonyForming Units) per capsule. Other ingredients in the powder are: microcrystalline cellulose, maltodextrin, silicon dioxide and magnesium stearate. Participants in this group will take one daily capsule orally starting at the time of recruitment (gestation week 12) and until delivery.
A preparation method of a novel BPs-PEG-Au nano composite material. The invention relates to a novel BPs-PEG-Au nano composite material. The invention aims to solve the problems of poor biological tissue penetrability, low biocompatibility and poor stability under physiological conditions of the conventional nano material. A novel BPs-PEG-Au nano composite material is designed and developed. TEM images of BPs-PEG, Au nanoparticles and BPs-PEG-Au are shown in the figure, and comparison shows that Au nanoparticles are successfully loaded on BPAnd (3) successfully preparing the novel BPs-PEG-Au nano composite material on the s-PEG. The preparation method comprises the following steps: ultrasonically preparing the ground large black scales into 2D black scale nanosheets (BPs) by using a liquid phase stripping method in an ice-water bath, and applying PEG-NH to the surfaces of the BPs 2 Modifying, and finally loading the prepared nano particles on PEG-NH 2 Modified BPs. The invention can obtain a preparation method of a novel BPs-PEG-Au nano composite material.
Levofloxacin tablets are indicated for inhalational anthrax (post-exposure) to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis in adults and pediatric patients, 6 months of age and older [see Dosage and Administartion (2.2)]. . The effectiveness of levofloxacin tablets are based on plasma concentrations achieved in humans, a surrogate endpoint reasonably likely to predict clinical benefit. Levofloxacin tablets has not been tested in humans for the post-exposure prevention of inhalation anthrax. The safety of levofloxacin tablets in adults for durations of therapy beyond 28 days or in pediatric patients for durations of therapy beyond 14 days has not been studied. 

Prolonged levofloxacin tablets therapy should only be used when the benefit outweighs the risk [see Clinical Studies (14.9)].
An anti-aging formula is provided. The anti-aging formula comprises a first microbial blend, a second microbial blend, chondroitin sulfate, vitamin D3, vitamin E, astragalus, and resveratrol. The first microbial blend comprises one or more lactobacillus bacteria, one or more streptococcus bacteria, one or more bifidobacterium bacteria, and kefir microflora. The second microbial blend comprises one or more lactobacillus bacterium, one or more lactococcus bacteria, and one or more bifidobacterium bacteria. The anti-aging formula is provided as a dietary supplement or drug for human use and is aimed at reversing aging. The formula targets particular genes and proteins that influence the process of aging, including Klotho, telomerase, and sirtuins. In addition, the anti-aging formula induces DNA time dilation, time reversal and quantum entanglement.
BACKGROUND: Instrumental activities of daily living (IADL) are typically self-reported ability to perform complex tasks vital for independent living. There is a need for a complementary objective, performance-based approach especially in tracking outcomes in visual rehabilitation for patients with irreversible vision impairment ("low vision"). Our goals are: (1) To describe the validity of timed performance of instrumental activities of daily living (timed IADL or TIADL) tasks in individuals with irreversible vision impairment, by examining its association with visual function (visual acuity, contrast sensitivity, visual field), (2) To explore the correlation between TIADL and self-reported IADL.
METHODS: Twenty TIADL tasks were administered to 88 patients (median age 63.3 years, IQR 37.4-78.0) recruited from the UAB Department of Ophthalmology, Callahan Eye Hospital Clinics. An average Z-score incorporating time and accuracy of task completion was constructed. Minor accuracy errors were penalized 1 standard deviation from their calculated Z-score and major accuracy errors were assigned maximum allotted time. Linear regression was used to analyze the association between TIADL score and measured visual acuity (Early Treatment Diabetic Retinopathy Study, ETDRS chart), contrast sensitivity (Pelli-Robson), and binocular visual field (Esterman) with an unadjusted model and an adjusted model accounting for age, comorbidities, and depression scale (Center for Epidemiological Studies Depression, CES-D). Pearson correlation was used to estimate the correlation between TIADL and IADL.
RESULTS: Increased time to task completion was associated with decreased visual function. Each decreased line of ETDRS read was associated with an increase of 0.002 (95% CI 0.001, 0.002) Z-score (P < 0.01). A decreased ability to discern each Pelli-Robson letter was associated with an increase of 0.26 (95% CI 0.19, 0.33) Z-score (P < 0.01). For each less Esterman target identified, there was an increase of 0.01 (95% CI 0.003, 0.02) Z-score. Self-reported IADL and TIADL were correlated for reading tasks such as newspapers, nutrients on food can, and microwave timer (P < 0.05).
CONCLUSIONS: Longer time to perform TIADL is associated with decreased visual acuity, contrast sensitivity, and binocular visual field. TIADL and self-reported IADL are significantly correlated for reading tasks providing an accurate, complementary outcome measure in clinical practice and research.
Danish birth cohort of men born in 1953 in the Metropolitan area of Copenhagen. These test-persons are divided into two groups based on performance in cognitive tests at late midlife compared to young adulthood; Positive expected performance and negative expected performance and sampled from a birth cohort of 11.532 men.
BACKGROUND: Medical Child Abuse (MCA) is a severe form of child abuse. In MCA, the caregiver abuses the child by exaggerating, fabricating, simulating, or inducing symptoms, and unnecessary, potentially harmful medical care harms the child. Bleeding is one of the most common manifestations of MCA. Diagnosis of MCA is challenging, and late diagnosis may increase the severity and complications. Once suspected, it is essential to apply all relevant methods of investigation to support and confirm the diagnosis, as soon as possible, as late diagnosis increases the risks.
CASE PRESENTATION: An 18-month-old boy was referred to the Pediatric Hematology by the Department of the Emergency with multiple admissions in a 2-week period for recurrent said-to-be bleeding episodes from different sites. Previously, he had been investigated for recurrent bleeding episodes in different hospitals for 4 months. In our center, the review of medical history, examination findings, and laboratory results showed some important inconsistencies leading to suspicion of MCA and the mother as the perpetrator. Then he was hospitalized for close observation. During hospitalization, multiple episodes of said-to-be bleeding were reported by the mother, but active bleeding was never observed by any hospital staff. No bleeding foci were detected in the nose or ears, supporting the diagnosis of MCA. After the file was forwarded to the prosecutor's office, the child was taken for institutional care, and no further bleeding was observed after separation from the mother. DNA, which was obtained from a so-called nosebleed during hospitalization, was analyzed and was reported to belong to the mother, confirming the diagnosis.
CONCLUSIONS: This case report draws attention to timely diagnoses by focusing on inconsistencies in the history and clinical signs and good clinical practices for the management of MCA, with a special emphasis on collecting evidence, including DNA samples, to confirm the diagnosis and help the legal process.
This study is a rigorous single-center, prospective, double-blinded, randomized controlled trial, aiming to evaluate the effectiveness of fecal microbiota transplantation (FMT) in improving bowel function for patients with major low anterior resection syndrome (LARS). A total of 40 subjects are planned to be recruited and randomly assigned to the experimental group and the control group at a 1:1 ratio. Prior to treatment, all subjects will undergo 16S sequencing of intestinal microbiota to assess their intestinal microecological status. During the treatment, a colonoscopic colonic catheter will be placed via the anus, with the experimental group receiving FMT solution matched to the patient's microbiota for intra-intestinal administration, while the control group will receive a standardized probiotic formula. To ensure the impartiality of the study, both patients and researchers administering the medication will be blinded to the trial drugs. The study will continuously observe and record bowel symptoms after 4 weeks of treatment as well as 16S sequencing results of intestinal microbiota after 8 weeks. Upon the completion of the entire study, the blinding will be revealed, and the results will be analyzed.
Psilocybin will be administered in pill form at a dose of .36 mg/kg. Psilocybin will be administered in one session over the course of 8 hours.
Educational Intervention At the initial visit (Visit 1), patients in the educational intervention group will complete a short Needs Assessment Questionnaire to help the investigator/nurse determine which section(s) of the tailored patient education booklet to give to, educate, and provide instruction on to the patient. This may, at the discretion of the investigator, include providing their patient with a peak flow meter and instructions on its use.Visit 2 will be scheduled for 1-month after the Visit 1 for the education intervention group. All educational materials provided at Visit 1 will be reviewed with the patient at Visit 2. The investigator/nurse will reassess the patient's use of the Turbuhaler® and asthma treatment plan. Patients will also be asked about any adverse events that may have occurred since Visit 1 and/or are observed at Visit 2. Once Visit 2 is completed with the patient, the investigator/nurse will complete the Educator Satisfaction Questionnaire.
A data handling system for a hospital or like establishment. The system keeps track of bed allocation, changes in inventory, and charges to patients, and also serves as a communication network for the hospital. Data is fed into the system in the form of pre-punched cards bearing patient information, inventory data, and commands or messages, and thus unskilled personnel can quickly feed data into the system without error. Message data is routed directly to teleprinters at addressed locations. Bed allocation and patient data, and charge and inventory data are respectively stored in separate magnetic drum storage areas. Searching facilities are provided which can locate desired data entries in either storage area and mark these entries for printout, and separate printout circuitry then transfers marked data items to the proper addresses in the proper format. At the end of each day, a final search is performed which produces a printout of all charges organized by patient number. A tally inventory search is also performed which produces a printout of inventory changes organized by item number and by department number. The tally search is cumulative, and a tally arithmetic unit summarizes inventory data for each separate item before printout. A running record is kept of each day's total charges, credits, and payments on account in a central core memory, and this record is continually updated by a central arithmetic unit.
A toxicoproteomic method for developing immunoassays to determine if a toxicant or a disease causes damage to a specific organ is disclosed. The discovery phase of the method involves the administration of a toxicant to an animal which will cause damage to a specific organ of the animal, which damage results in the production of an oxidatively modified, organ specific protein(s). Blood serum, which includes the modified protein(s) released from the organ following damage, is collected from the animal. The modified protein(s) is isolated from serum by immunoaffinity purification using antibodies directed against any number of damage-related, amino acid modifications, in this instance, nitrotyrosine, chlorotyrosine and methionine sulfoxide. Its function as a biomarker is validated by determining if the modified protein(s) is specific to the tissue or organ of interest. If the modified protein is organ specific, an antibody is raised against it, and this antibody is utilized in immunoassays to (1) measure the concentration of the protein in serum and, (2) together with antibodies against the modified amino acids found on its surface used to determine the type and extent of modification found on the protein. The assays of the present invention have utility for the toxicological screening of newly developed drugs, evaluating patients diagnostically or for organ involvement in disease, the study of cellular responses to various toxicants, and the determination of peripheral redox status.
Patients were given consolidation therapy for 8 cycles (1 cycle = 21 days) with the combination bortezomib plus dexamethasone. Patients received each cycle: the standard dose of bortezomib (1.3 mg/m2) on days 1, 4, 8 and 11 and 3 days of dexamethasone at 40 mg total dose per day given on days 1, 8 and 15.
studies conducted with marker substrates of CYP450 enzymes (CYP1A2, -2A6, -2C9, -2D6, -2E1, -3A4) showed minimal inhibition of these enzymes by memantine. In addition, i studies indicate that at concentrations exceeding those associated with efficacy, memantine does not induce the cytochrome P450 isozymes CYP1A2, -2C9, -2E1 and -3A4/5. No pharmacokinetic interactions with drugs metabolized by these enzymes are expected. In vitron vitro

Pharmacokinetic studies evaluated the potential of memantine for interaction with donepezil (See ) and bupropion. Coadministration of memantine with the AChE inhibitor donepezil HCl does not affect the pharmacokinetics of either compound. Memantine did not affect the pharmacokinetics of the CYP2B6 substrate bupropion or its metabolite hydroxybupropion. Section Use with Cholinesterase Inhibitors 7.7
The invention provides high-purity geniposide as well as preparation and clinical application of preparations thereof. Gardenia is a dried and matured fruit of rubiaceae plant gardenia and has liver-protecting, chole-promoting, pressure-reducing, heat-clearing, cold-promoting and diarrhea-relieving functions and the like. The geniposide is a product which is obtained by refining the dried and matured fruit of the rubiaceae plant gardenia by virtue of a high-technology production process and is an iridoid glycoside compound. The geniposide is used for treating cardiovascular and cerebrovascular diseases, hepatic and biliary diseases, diabetes mellitus and the like. At present, a lot of methods for extracting the geniposide and gardenia pigment from the gardenia are reported in documents, but a plenty of problems exit, such as the product contains high impurity content so that the requirements of customers at home and abroad can not be satisfied, the production cost is high, the yield is low, the economic benefits are poor, the methods are not suitable for industrial production, and the like. According to the invention, the problems are solved. The high-purity geniposide is obtained by virtue of extraction and purification of gardenia and is prepared into proper preparations such as tablets, capsules, particles, injecta, powder injections, infusion solutions and the like to be applied to the clinic for treating cardiovascular and cerebrovascular diseases, hepatic and biliary diseases, diabetes mellitus and the like.
Multielectrode arrays (MEAs) are the method of choice for electrophysiological characterization of cardiomyocyte monolayers. The field potentials recorded using an MEA are like extracellular electrograms recorded from the myocardium using conventional electrodes. Nevertheless, different criteria are used to interpret field potentials and extracellular electrograms, which hamper correct interpretation and translation to the patient. To validate the criteria for interpretation of field potentials, we used neonatal rat cardiomyocytes to generate monolayers. We recorded field potentials using an MEA and simultaneously recorded action potentials using sharp microelectrodes. In parallel, we recreated our experimental setting in silico and performed simulations. We show that the amplitude of the local RS complex of a field potential correlated with conduction velocity in silico but not in vitro. The peak time of the T wave in field potentials exhibited a strong correlation with APD90 while the steepest upslope correlated well with APD50. However, this relationship only holds when the T wave displayed a biphasic pattern. Next, we simulated local extracellular action potentials (LEAPs). The shape of the LEAP differed markedly from the shape of the local action potential, but the final duration of the LEAP coincided with APD90. Criteria for interpretation of extracellular electrograms should be applied to field potentials. This will provide a strong basis for the analysis of heterogeneity in conduction velocity and repolarization in cultured monolayers of cardiomyocytes. Finally, a LEAP is not a recording of the local action potential but is generated by intracellular current provided by neighboring cardiomyocytes and is superior to field potential duration in estimating APD90.NEW & NOTEWORTHY We present a physiological basis for the interpretation of multielectrode array-derived, extracellular, electrical signals.
Low FODMAP diet (LFD) Each IBS patient randomized to the Australian exclusion diet, Low FODMAP diet (LFD) group (n=52) will when allocated to LFD group have a one-hour counseling to the LFD by a nutritionist at the hospital. Within this one hour a diet anamnesis of the patient will be made in order to register the High FODMAP foods the patient is consuming (important that one find good low FODMAP substitutions). Based on the diet anamnesis optimization of the low FODMAP diet counseling can be made. They will receive hands-out with recipes, tips, meal plans, list of suitable low FODMAP foods and folder of foods they should avoid- most of information in the LFD folder patients will also find in the app 'Low FODMAP diet' which they will receive free of charge.
A system is provided for establishing a compliance zone and monitoring interactions therewith. The system includes a compliance zone designator and a wearable device. The compliance zone designator transmits an ultrasound signal to establish the compliance zone. The ultrasound signal may be encoded with information on the compliance zone. The compliance zone designator is configured for placement at a location in which the compliance zone is desired. The wearable device is separate from the compliance zone designator. The wearable device includes a compliance zone recognition component configured to recognize the compliance zone and identify one or more pre-defined interaction criteria for the compliance zone.; When the wearable device is within the compliance zone, the compliance zone recognition component recognizes the compliance zone and identifies the interaction criteria of the compliance zone. Based on the interaction criteria the wearable device determines and records compliance with the interaction criteria. The recorded data is optionally used to set off real-time alerts. The recorded data is also optionally used in subsequent analysis and documentation of compliance with protocols.